IgA Nephropathy Market - A Global and Regional Analysis: Focus on Regional Analysis - Analysis and Forecast, 2025-2035
Hard copy option is available on any of the options above at an additional charge of $500. Please email us at [email protected] with your request.
This report will be delivered in 7-10 working days.Market Lifecycle Stage
The global IgA nephropathy market is currently in the growth stage of its lifecycle, driven by increasing awareness, improved diagnostic capabilities, and advancements in renal treatment options. The market is expanding as novel therapies, such as complement inhibitors and non-immunosuppressive drugs, are gaining traction, addressing the unmet need for more effective renal treatments. With ongoing research and development, pharmaceutical companies are investing heavily in clinical trials to bring new, targeted therapies to market. Additionally, regulatory bodies are accelerating the approval process for innovative renal drugs, further fueling market growth. Despite this positive momentum, challenges such as high treatment costs and the variability in disease progression may hinder rapid expansion. As a result, the market is expected to continue growing, although competition and price pressures will likely intensify as more treatments emerge.
Impact
Recent Developments
Drivers:
Product/Innovation Strategy: Product launches and innovations in the global IgA nephropathy market are focused on advancing treatment options to improve patient care. These innovations aim to enhance the efficacy of therapies and streamline the detection and management of the disease. Key players in the market, such as Novartis, and Travere Therapeutics, Inc., have been involved in the development of therapies for IgA nephropathy.
Competitive Strategy: Enterprises led by market leaders in the global IgA nephropathy market are continuously working on updating their product portfolios with innovative treatments to maintain competitiveness. A detailed competitive benchmarking of the key players has been conducted, providing insights into how these companies compare in terms of product offerings, market share, and innovation. This benchmarking provides readers with a clear understanding of the market landscape and the positions of the leading players. Additionally, comprehensive competitive strategies, such as partnerships, agreements, and collaborations, will help readers identify untapped revenue opportunities in the market.
Key Market Players and Competition Synopsis
The companies that are profiled have been selected based on inputs gathered from primary experts and by analyzing company coverage, product portfolio, and market penetration.
Some of the prominent names established in this market are:
This report will be delivered in 7-10 working days.Market Lifecycle Stage
The global IgA nephropathy market is currently in the growth stage of its lifecycle, driven by increasing awareness, improved diagnostic capabilities, and advancements in renal treatment options. The market is expanding as novel therapies, such as complement inhibitors and non-immunosuppressive drugs, are gaining traction, addressing the unmet need for more effective renal treatments. With ongoing research and development, pharmaceutical companies are investing heavily in clinical trials to bring new, targeted therapies to market. Additionally, regulatory bodies are accelerating the approval process for innovative renal drugs, further fueling market growth. Despite this positive momentum, challenges such as high treatment costs and the variability in disease progression may hinder rapid expansion. As a result, the market is expected to continue growing, although competition and price pressures will likely intensify as more treatments emerge.
Impact
- Increasing demand for IgA nephropathy therapies is anticipated to support the growth of the global IgA nephropathy market during the forecast period 2025-2035.
- The global IgA nephropathy market is expected to grow at a significant rate due to advancements in diagnostic technologies, the development of innovative therapies, and increasing awareness among patients and healthcare providers.
Recent Developments
- Regulatory Activities: In April 2025, the U.S. FDA granted accelerated approval for Novartis’ Vanrafia (atrasentan) for the treatment of primary immunoglobulin A nephropathy.
- Partnerships: In March 2025, Folia Health and Novartis Pharmaceuticals, Inc. announced their collaboration on an innovative at-home observational real-world evidence initiative aimed at supporting individuals with IgA nephropathy.
- Regulatory Activities: In November 2024, South Korea approved Everest Medicines' NEFECON for the treatment of primary IgA nephropathy.
- Regulatory Activities: In September 2024, Ligand partner Travere Therapeutics received FDA approval for FILSPARI (sparsentan), the only non-immunosuppressive treatment that significantly slows kidney function decline in IgA nephropathy.
Drivers:
- Increasing Prevalence of IgA Nephropathy
- Continuous Advancements in Treatment Options
- Improved Diagnosis and Awareness
- High Treatment Costs
- Limited Awareness in Developing Markets
Product/Innovation Strategy: Product launches and innovations in the global IgA nephropathy market are focused on advancing treatment options to improve patient care. These innovations aim to enhance the efficacy of therapies and streamline the detection and management of the disease. Key players in the market, such as Novartis, and Travere Therapeutics, Inc., have been involved in the development of therapies for IgA nephropathy.
Competitive Strategy: Enterprises led by market leaders in the global IgA nephropathy market are continuously working on updating their product portfolios with innovative treatments to maintain competitiveness. A detailed competitive benchmarking of the key players has been conducted, providing insights into how these companies compare in terms of product offerings, market share, and innovation. This benchmarking provides readers with a clear understanding of the market landscape and the positions of the leading players. Additionally, comprehensive competitive strategies, such as partnerships, agreements, and collaborations, will help readers identify untapped revenue opportunities in the market.
Key Market Players and Competition Synopsis
The companies that are profiled have been selected based on inputs gathered from primary experts and by analyzing company coverage, product portfolio, and market penetration.
Some of the prominent names established in this market are:
- Novartis
- F. Hoffmann-La Roche
- Ionis Pharmaceuticals
- Vertex Pharmaceuticals
- Otsuka Pharmaceutical
- Biogen
- Arrowhead Pharmaceuticals
- NovelMed
- Q32 Bio
- Walden Biosciences
- Takeda Pharmaceutical
- Vera Therapeutics
- Biocity Biopharmaceutics Co., Ltd.
- Calliditas Therapeutics AB
- Travere Therapeutics, Inc.
- Alexion Pharmaceuticals, Inc.
Executive Summary
Scope of Study
1. GLOBAL IGA NEPHROPATHY MARKET: MARKET OUTLOOK
1.1 Industry Outlook
1.1.1 Market Overview and Ecosystem
1.1.2 Market Trends
1.1.3 Epidemiological Analysis of IgA Nephropathy
1.1.3.1 By Region
1.1.3.1.1 U.S.
1.1.3.1.2 EU5
1.1.3.1.3 Rest-of-the-World
1.1.4 Clinical Trials
1.1.4.1 By Phase
1.1.4.2 By Sponsor Type
1.1.5 Regulatory Landscape / Compliance
1.1.5.1 Legal Requirement and Framework in the U.S.
1.1.5.2 Legal Requirement and Framework in the E.U.
1.1.5.3 Legal Requirement and Framework in Asia-Pacific
1.1.5.4 Legal Requirement and Framework in Rest-of-the-World
1.2 Market Dynamics
1.2.1 Impact Analysis
1.2.2 Market Drivers
1.2.3 Market Restraints
1.2.4 Market Opportunities
2. GLOBAL IGA NEPHROPATHY MARKET (BY REGION), $MILLION, 2023-2035
2.1 North America
2.1.1 Key Findings
2.1.2 Market Dynamics
2.1.3 Market Sizing and Forecast
2.1.3.1 North America IgA Nephropathy Market (by Country)
2.1.3.1.1 U.S.
2.1.3.1.2 Canada
2.2 Europe
2.2.1 Key Findings
2.2.2 Market Dynamics
2.2.3 Market Sizing and Forecast
2.2.3.1 Europe IgA Nephropathy Market (by Country)
2.2.3.1.1 U.K.
2.2.3.1.2 Germany
2.2.3.1.3 France
2.2.3.1.4 Italy
2.2.3.1.5 Spain
2.2.3.1.6 Rest-of-Europe
2.3 Asia-Pacific
2.3.1 Key Findings
2.3.2 Market Dynamics
2.3.3 Market Sizing and Forecast
2.3.3.1 Asia-Pacific IgA Nephropathy Market (by Country)
2.3.3.1.1 Japan
2.3.3.1.2 China
2.3.3.1.3 Rest-of-Asia-Pacific
2.4 Rest-of-the-World
2.4.1 Key Findings
2.4.2 Market Dynamics
2.4.3 Market Sizing and Forecast
3. GLOBAL IGA NEPHROPATHY MARKET - COMPETITIVE BENCHMARKING AND COMPANY PROFILES
3.1 Competitive Landscape
3.1.1 Key Strategies and Developments by Company
3.1.1.1 Funding Activities
3.1.1.2 Mergers and Acquisitions
3.1.1.3 Regulatory Approvals
3.1.1.4 Partnerships, Collaborations and Business Expansions
3.1.2 Key Developments Analysis
3.2 Company Profiles
3.2.1 Novartis
3.2.1.1 Company Overview
3.2.1.2 Product Portfolio
3.2.1.3 Target Customers/End Users
3.2.1.4 Analyst View
3.2.2 F. Hoffmann-La Roche
3.2.2.1 Company Overview
3.2.2.2 Product Portfolio
3.2.2.3 Target Customers/End Users
3.2.2.4 Analyst View
3.2.3 Ionis Pharmaceuticals
3.2.3.1 Company Overview
3.2.3.2 Product Portfolio
3.2.3.3 Target Customers/End Users
3.2.3.4 Analyst View
3.2.4 Vertex Pharmaceuticals
3.2.4.1 Company Overview
3.2.4.2 Product Portfolio
3.2.4.3 Target Customers/End Users
3.2.4.4 Analyst View
3.2.5 Otsuka Pharmaceutical
3.2.5.1 Company Overview
3.2.5.2 Product Portfolio
3.2.5.3 Target Customers/End Users
3.2.5.4 Analyst View
3.2.6 Biogen
3.2.6.1 Company Overview
3.2.6.2 Product Portfolio
3.2.6.3 Target Customers/End Users
3.2.6.4 Analyst View
3.2.7 Arrowhead Pharmaceuticals
3.2.7.1 Company Overview
3.2.7.2 Product Portfolio
3.2.7.3 Target Customers/End Users
3.2.7.4 Analyst View
3.2.8 NovelMed
3.2.8.1 Company Overview
3.2.8.2 Product Portfolio
3.2.8.3 Target Customers/End Users
3.2.8.4 Analyst View
3.2.9 Q32 Bio
3.2.9.1 Company Overview
3.2.9.2 Product Portfolio
3.2.9.3 Target Customers/End Users
3.2.9.4 Analyst View
3.2.10 Takeda Pharmaceutical
3.2.10.1 Company Overview
3.2.10.2 Product Portfolio
3.2.10.3 Target Customers/End Users
3.2.10.4 Analyst View
3.2.11 Vera Therapeutics
3.2.11.1 Company Overview
3.2.11.2 Product Portfolio
3.2.11.3 Target Customers/End Users
3.2.11.4 Analyst View
3.2.12 Biocity Biopharmaceutics Co., Ltd.
3.2.12.1 Company Overview
3.2.12.2 Product Portfolio
3.2.12.3 Target Customers/End Users
3.2.12.4 Analyst View
3.2.13 Calliditas Therapeutics AB
3.2.13.1 Company Overview
3.2.13.2 Product Portfolio
3.2.13.3 Target Customers/End Users
3.2.13.4 Analyst View
3.2.14 Travere Therapeutics, Inc.
3.2.14.1 Company Overview
3.2.14.2 Product Portfolio
3.2.14.3 Target Customers/End Users
3.2.14.4 Analyst View
3.2.15 Alexion Pharmaceuticals, Inc.
3.2.15.1 Company Overview
3.2.15.2 Product Portfolio
3.2.15.3 Target Customers/End Users
3.2.15.4 Analyst View
4. RESEARCH METHODOLOGY
Scope of Study
1. GLOBAL IGA NEPHROPATHY MARKET: MARKET OUTLOOK
1.1 Industry Outlook
1.1.1 Market Overview and Ecosystem
1.1.2 Market Trends
1.1.3 Epidemiological Analysis of IgA Nephropathy
1.1.3.1 By Region
1.1.3.1.1 U.S.
1.1.3.1.2 EU5
1.1.3.1.3 Rest-of-the-World
1.1.4 Clinical Trials
1.1.4.1 By Phase
1.1.4.2 By Sponsor Type
1.1.5 Regulatory Landscape / Compliance
1.1.5.1 Legal Requirement and Framework in the U.S.
1.1.5.2 Legal Requirement and Framework in the E.U.
1.1.5.3 Legal Requirement and Framework in Asia-Pacific
1.1.5.4 Legal Requirement and Framework in Rest-of-the-World
1.2 Market Dynamics
1.2.1 Impact Analysis
1.2.2 Market Drivers
1.2.3 Market Restraints
1.2.4 Market Opportunities
2. GLOBAL IGA NEPHROPATHY MARKET (BY REGION), $MILLION, 2023-2035
2.1 North America
2.1.1 Key Findings
2.1.2 Market Dynamics
2.1.3 Market Sizing and Forecast
2.1.3.1 North America IgA Nephropathy Market (by Country)
2.1.3.1.1 U.S.
2.1.3.1.2 Canada
2.2 Europe
2.2.1 Key Findings
2.2.2 Market Dynamics
2.2.3 Market Sizing and Forecast
2.2.3.1 Europe IgA Nephropathy Market (by Country)
2.2.3.1.1 U.K.
2.2.3.1.2 Germany
2.2.3.1.3 France
2.2.3.1.4 Italy
2.2.3.1.5 Spain
2.2.3.1.6 Rest-of-Europe
2.3 Asia-Pacific
2.3.1 Key Findings
2.3.2 Market Dynamics
2.3.3 Market Sizing and Forecast
2.3.3.1 Asia-Pacific IgA Nephropathy Market (by Country)
2.3.3.1.1 Japan
2.3.3.1.2 China
2.3.3.1.3 Rest-of-Asia-Pacific
2.4 Rest-of-the-World
2.4.1 Key Findings
2.4.2 Market Dynamics
2.4.3 Market Sizing and Forecast
3. GLOBAL IGA NEPHROPATHY MARKET - COMPETITIVE BENCHMARKING AND COMPANY PROFILES
3.1 Competitive Landscape
3.1.1 Key Strategies and Developments by Company
3.1.1.1 Funding Activities
3.1.1.2 Mergers and Acquisitions
3.1.1.3 Regulatory Approvals
3.1.1.4 Partnerships, Collaborations and Business Expansions
3.1.2 Key Developments Analysis
3.2 Company Profiles
3.2.1 Novartis
3.2.1.1 Company Overview
3.2.1.2 Product Portfolio
3.2.1.3 Target Customers/End Users
3.2.1.4 Analyst View
3.2.2 F. Hoffmann-La Roche
3.2.2.1 Company Overview
3.2.2.2 Product Portfolio
3.2.2.3 Target Customers/End Users
3.2.2.4 Analyst View
3.2.3 Ionis Pharmaceuticals
3.2.3.1 Company Overview
3.2.3.2 Product Portfolio
3.2.3.3 Target Customers/End Users
3.2.3.4 Analyst View
3.2.4 Vertex Pharmaceuticals
3.2.4.1 Company Overview
3.2.4.2 Product Portfolio
3.2.4.3 Target Customers/End Users
3.2.4.4 Analyst View
3.2.5 Otsuka Pharmaceutical
3.2.5.1 Company Overview
3.2.5.2 Product Portfolio
3.2.5.3 Target Customers/End Users
3.2.5.4 Analyst View
3.2.6 Biogen
3.2.6.1 Company Overview
3.2.6.2 Product Portfolio
3.2.6.3 Target Customers/End Users
3.2.6.4 Analyst View
3.2.7 Arrowhead Pharmaceuticals
3.2.7.1 Company Overview
3.2.7.2 Product Portfolio
3.2.7.3 Target Customers/End Users
3.2.7.4 Analyst View
3.2.8 NovelMed
3.2.8.1 Company Overview
3.2.8.2 Product Portfolio
3.2.8.3 Target Customers/End Users
3.2.8.4 Analyst View
3.2.9 Q32 Bio
3.2.9.1 Company Overview
3.2.9.2 Product Portfolio
3.2.9.3 Target Customers/End Users
3.2.9.4 Analyst View
3.2.10 Takeda Pharmaceutical
3.2.10.1 Company Overview
3.2.10.2 Product Portfolio
3.2.10.3 Target Customers/End Users
3.2.10.4 Analyst View
3.2.11 Vera Therapeutics
3.2.11.1 Company Overview
3.2.11.2 Product Portfolio
3.2.11.3 Target Customers/End Users
3.2.11.4 Analyst View
3.2.12 Biocity Biopharmaceutics Co., Ltd.
3.2.12.1 Company Overview
3.2.12.2 Product Portfolio
3.2.12.3 Target Customers/End Users
3.2.12.4 Analyst View
3.2.13 Calliditas Therapeutics AB
3.2.13.1 Company Overview
3.2.13.2 Product Portfolio
3.2.13.3 Target Customers/End Users
3.2.13.4 Analyst View
3.2.14 Travere Therapeutics, Inc.
3.2.14.1 Company Overview
3.2.14.2 Product Portfolio
3.2.14.3 Target Customers/End Users
3.2.14.4 Analyst View
3.2.15 Alexion Pharmaceuticals, Inc.
3.2.15.1 Company Overview
3.2.15.2 Product Portfolio
3.2.15.3 Target Customers/End Users
3.2.15.4 Analyst View
4. RESEARCH METHODOLOGY
LIST OF FIGURES
Figure: Global IgA Nephropathy Market, Market Overview
Figure: Global IgA Nephropathy Market, Epidemiological Analysis, U.S.
Figure: Global IgA Nephropathy Market Coverage
Figure: Global IgA Nephropathy Market Key Trends, Impact Analysis, 2023-2035
Figure: Global IgA Nephropathy Market, Competitive Landscape, January 2022-April 2025
Figure: Global IgA Nephropathy Market, Market Overview
Figure: Global IgA Nephropathy Market, Epidemiological Analysis, U.S.
Figure: Global IgA Nephropathy Market Coverage
Figure: Global IgA Nephropathy Market Key Trends, Impact Analysis, 2023-2035
Figure: Global IgA Nephropathy Market, Competitive Landscape, January 2022-April 2025
LIST OF TABLES
Table: Global IgA Nephropathy Market, Regulatory Scenario
Table: Global IgA Nephropathy Market Dynamics, Impact Analysis
Table: Global IgA Nephropathy Market, Regulatory Scenario
Table: Global IgA Nephropathy Market Dynamics, Impact Analysis
